Cargando…

Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90

PURPOSE: To explore the clinical distribution characteristics and antimicrobial susceptibilities of carbapenem-resistant Escherichia coli (CR-ECO) in Hebei Province, China, from 2017 to 2019, and provide data on the treatment of this bacterial infection and the prevention of its spread. MATERIALS AN...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wei, Li, Zhirong, Wang, Na, Yang, Zhicong, Li, Jia, Li, Caiqing, Han, Xuying, Liu, Jinlu, Li, Liping, Wang, Shuwang, Zhan, Minghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594617/
https://www.ncbi.nlm.nih.gov/pubmed/34795488
http://dx.doi.org/10.2147/IDR.S334283
_version_ 1784600022771302400
author Zhang, Wei
Li, Zhirong
Wang, Na
Yang, Zhicong
Li, Jia
Li, Caiqing
Han, Xuying
Liu, Jinlu
Li, Liping
Wang, Shuwang
Zhan, Minghua
author_facet Zhang, Wei
Li, Zhirong
Wang, Na
Yang, Zhicong
Li, Jia
Li, Caiqing
Han, Xuying
Liu, Jinlu
Li, Liping
Wang, Shuwang
Zhan, Minghua
author_sort Zhang, Wei
collection PubMed
description PURPOSE: To explore the clinical distribution characteristics and antimicrobial susceptibilities of carbapenem-resistant Escherichia coli (CR-ECO) in Hebei Province, China, from 2017 to 2019, and provide data on the treatment of this bacterial infection and the prevention of its spread. MATERIALS AND METHODS: A total of 1439 CR-ECO strains were collected from 2017 to 2019 in Hebei Province, China. Drug sensitivity tests were performed using the minimum inhibitory concentration (MIC) method, and the data were analyzed statistically using WHONET5.6 software. RESULTS: A total of 54,377 strains of Escherichia coli were isolated in Hebei Province from 2017 to 2019, of which 1439 strains were CR-ECO (2.65%). The highest proportion (33.78%) of strains was isolated from urine, and the detection rate showed a slow downward trend over the past 3 years. CR-ECO was mainly detected in densely populated and economically developed areas. Of all the patients, 54.2% were from the medical ward; the ratio of male to female patients with CR-ECO infections was 1.35:1; elderly patients and adults accounted for 59.6% and 30.8%, respectively, whereas minors and newborns accounted for 4.9% and 4.7%, respectively. For CR-ECO, the drug resistance rates to β-lactams were all higher than 80% and there was an annual increasing trend, while the drug resistance rates to quinolones remained nearly unchanged. The rate of resistance to aminoglycosides was relatively low, especially to amikacin (approximately 22%). The MIC50 of other antibacterial drugs, except amikacin, was equal to or higher than the break point of drug resistance. CONCLUSION: From 2017 to 2019, the isolation rate of CR-ECO in Hebei Province, China, remained stable; however, the drug resistance rate showed an upward trend, primarily in cases of urinary tract infections in older men; the resistance rate to amikacin was the lowest.
format Online
Article
Text
id pubmed-8594617
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85946172021-11-17 Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 Zhang, Wei Li, Zhirong Wang, Na Yang, Zhicong Li, Jia Li, Caiqing Han, Xuying Liu, Jinlu Li, Liping Wang, Shuwang Zhan, Minghua Infect Drug Resist Original Research PURPOSE: To explore the clinical distribution characteristics and antimicrobial susceptibilities of carbapenem-resistant Escherichia coli (CR-ECO) in Hebei Province, China, from 2017 to 2019, and provide data on the treatment of this bacterial infection and the prevention of its spread. MATERIALS AND METHODS: A total of 1439 CR-ECO strains were collected from 2017 to 2019 in Hebei Province, China. Drug sensitivity tests were performed using the minimum inhibitory concentration (MIC) method, and the data were analyzed statistically using WHONET5.6 software. RESULTS: A total of 54,377 strains of Escherichia coli were isolated in Hebei Province from 2017 to 2019, of which 1439 strains were CR-ECO (2.65%). The highest proportion (33.78%) of strains was isolated from urine, and the detection rate showed a slow downward trend over the past 3 years. CR-ECO was mainly detected in densely populated and economically developed areas. Of all the patients, 54.2% were from the medical ward; the ratio of male to female patients with CR-ECO infections was 1.35:1; elderly patients and adults accounted for 59.6% and 30.8%, respectively, whereas minors and newborns accounted for 4.9% and 4.7%, respectively. For CR-ECO, the drug resistance rates to β-lactams were all higher than 80% and there was an annual increasing trend, while the drug resistance rates to quinolones remained nearly unchanged. The rate of resistance to aminoglycosides was relatively low, especially to amikacin (approximately 22%). The MIC50 of other antibacterial drugs, except amikacin, was equal to or higher than the break point of drug resistance. CONCLUSION: From 2017 to 2019, the isolation rate of CR-ECO in Hebei Province, China, remained stable; however, the drug resistance rate showed an upward trend, primarily in cases of urinary tract infections in older men; the resistance rate to amikacin was the lowest. Dove 2021-11-12 /pmc/articles/PMC8594617/ /pubmed/34795488 http://dx.doi.org/10.2147/IDR.S334283 Text en © 2021 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhang, Wei
Li, Zhirong
Wang, Na
Yang, Zhicong
Li, Jia
Li, Caiqing
Han, Xuying
Liu, Jinlu
Li, Liping
Wang, Shuwang
Zhan, Minghua
Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90
title Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90
title_full Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90
title_fullStr Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90
title_full_unstemmed Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90
title_short Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90
title_sort clinical distribution characteristics of 1439 carbapenem-resistant escherichia coli strains in china: drug resistance, geographical distribution, antibiotic mic50/90
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594617/
https://www.ncbi.nlm.nih.gov/pubmed/34795488
http://dx.doi.org/10.2147/IDR.S334283
work_keys_str_mv AT zhangwei clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090
AT lizhirong clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090
AT wangna clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090
AT yangzhicong clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090
AT lijia clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090
AT licaiqing clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090
AT hanxuying clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090
AT liujinlu clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090
AT liliping clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090
AT wangshuwang clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090
AT zhanminghua clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090